Dr. Teri Schreiner’s work in MS is focused on the rarest of patients: children. The vast majority of newly-diagnosed patients are roughly between the ages of 25 and 45, but…
Read More
Despite New Technology and Guidelines, Diagnosing MS isn’t Always Straightforward The RMMSC’s Dr. Amanda Piquet specializes in MS and other autoimmune neurological disorders. We spoke to Dr. Piquet to get…
Early and accurate diagnosis of MS is probably the most important component of MS treatment — getting patients on effective therapies as quickly as possible has a dramatic effect on…
By Thomas Stewart, M.S., J.D., PA-C | The Americans with Disabilities Act (ADA) is the primary protection provided to workers with disabilities who want to stay in the work force. The…
Pick Your Summit and Hit the Trails in Support of the RMMSC The 2019 MS4MS campaign is in full swing, and we hope you’ll join us on the trails this…
Finding a ‘Typical’ Presentation in a Disease that’s Anything But Typical If you’re reading this, you or a loved one probably have direct experience with receiving an MS diagnosis. And…
MS doesn’t mean losing your mind. Whether you are newly diagnosed or an experienced person with MS, understanding your changing cognitive challenges leads to identifying coping skills. Join the RMMSC and author…
The Rocky Mountain MS Center’s 2019 Spring Education Summit was held Saturday, April 13 at the Anschutz Medical Campus in Aurora. Below is a recap of the entire Summit, including…
The US Food and Drug Administration (FDA) has approved oral cladribine (brand named Mavenclad®, EMD Serono) for the treatment of adults with relapsing forms of MS, including relapsing-remitting MS and…
The US Food and Drug Administration (FDA) has approved oral Siponimod (brand named Mayzent®, Novartis International AG) to treat clinically isolated syndrome (an initial neurological episode), relapsing forms of MS,…
You're Reading:
About the Author
This content was compiled by Rocky Mountain MS Center staff members.